Virtual product theater presentations on neurology and neuroscience, brought to you by industry leaders
Please see our featured Spotlights below!
Disclaimer: The ANA Spotlights videos are paid advertisements and viewers are not to consider the contents as an endorsement of products or services by the ANA. The materials, information or opinions provided during the videos are solely those of the individuals and companies involved and do not necessarily represent those of the ANA.
NMD Symposium: The role of neuromuscular transmission failure and ClC-1 inhibition as a novel therapeutic approach across neuromuscular diseases; positive proof of mechanism in patients with myasthenia gravis
In a group of neuromuscular diseases, dysfunctions that cause excitation failures of muscle fiber action potential at the neuromuscular junction (NMJ) lead to excessive and, in some cases, life-threatening muscle weakness. Multiple cellular mechanisms can cause NMJ transmission failure in these diseases, commonly affecting the release of acetylcholine from pre-synaptic nerve terminals or the post-synaptic ability of muscle fibers to respond to that release.
During this symposium, we will examine how different neuromuscular diseases affect the NMJ transmission including spinal muscular atrophy, Charcot-Marie Tooth and myasthenia gravis. We will review current clinical evidence of these abnormalities in patients, their correlation with the severity of their symptoms and the potential of skeletal muscle-specific ClC-1 ion channels inhibition to correct these deficits.
Unpublished data results from a proof of mechanism study utilizing a novel and first in class ClC-1 inhibitor in patients with myasthenia gravis will be presented and discussed; patients enrolled in a randomized, double-blind, placebo-controlled, three-way crossover study received a ClC-1 inhibitor and demonstrated clinically relevant improvements.
- Guest: Dr. W. David Arnold, University of Missouri
- Guest: Dr. Thomas H. Pedersen, NMD Pharma
- Guest: Dr. Jorge A. Quiroz, NMD Pharma
Eisai Inc. Symposium: Alzheimer's disease: an expert discussion on the evolving treatment landscape
- Guest: Jessica Zweling, MD, MS, FAAN
- Guest: Darren Gitelman, MD, FAAN, FANA
ANA Spotlights Mayo Clinic's Jeremy Cutsforth-Gregory, MD, FAAN Assistant Professor of Neurology Director, CSF Dynamics Clinic
In this ~5 minute video, Dr. Jeremy Cutsforth-Gregory, MD, FAAN of Mayo Clinic's Neurology team reviews a pioneering procedure to reduce the procedural risk and greatly improve the outcome for patients with CSF venous fistula.
Please follow these links to learn more about Dr. Cutsforth-Gregory and collaborating with Mayo Clinic's Neurology & Neurosurgery teams:
- Interviewer/Producer: Dr. Jeremy Custforth-Gregory, MD, FAAN, Mayo Clinic's Neurology team
ANA Spotlights Mayo Clinic's Andrew McKeon, M.B., B.Ch., M.D.
Please follow these links to learn more abo
In this 30 minute video, Dr. Andrew McKeon of Mayo Clinic's Neurology team discusses the rationale and benefits of collaborating with the Mayo Clinic team in the diagnosis of autoimmune CNS disorders.
Please follow these links to learn more about Dr. McKeon and collaborating with Mayo Clinic's Neurology & Neurosurgery teams:
- Interviewer/Producer: Dr. Andrew McKeon, M.B., B.CH., M.D., Mayo Clinic's Neurology & Neurosurgery teams